Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma
Abstract Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T‐cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high‐dose cyclophosphamide (Turbo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.1039 |